Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China
August 05, 2021 at 02:00 am EDT
Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong and Macau. Under the terms of the agreement, Inmagene will obtain exclusive rights to develop and commercialize fostamatinib in all potential indications in China. In return, Kissei will receive an upfront payment and milestone payments based on the progress of development and commercialization.